Peanut Allergy 2019

As the draft report notes, “the quality of life outcomes for the phase 3 trials have not yet been published. It is [therefore] challenging to fully evaluate the impact of these therapies without placebo-controlled assessments of the change in quality of life.” Given the reality of such limited data – particularly about patient perspectives and quality – we believe it is too early for ICER to conduct this assessment.

Continue Reading
  • 1
  • 2
Close Menu